Receptor activator of nuclear factor κB ligand plays a nonredundant role in doxorubicin-induced apoptosis

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1772-1775

  Müller, Ingo ^a   Pfister, Stefan M ^a   Grohs, Ulrike ^a   Zweigner, Janine ^b   Handgretinger, Rupert ^b   Niethammer, Dietrich ^a   Bruchelt, Gernot ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD95 LIGAND; CYTOCHROME C; DOXORUBICIN; HYBRID PROTEIN; LIGAND; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MITOCHONDRION; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARRIER PROTEINS; CELL LINE; CYTOCHROME C GROUP; DOXORUBICIN; DRUG SYNERGISM; HUMANS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; NF-KAPPA B; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; STAUROSPORINE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344406083     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
2. Tolomeo, M., Dusonchet, L., Meli, M., Grimaudo, S., D'Alessandro, N., Papoff, G., Ruberti, G., and Rausa, L. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ., 5: 735-742, 1998.
3. Muller, I., Jenner, A., Bruchelt, G., Niethammer, D., and Halliwell, B. Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem. Biophys. Res. Commun., 230: 254-257, 1997.
4. Houghton, J. A. Apoptosis and drug response. Curr. Opin. Oncol., 11: 475-481, 1999.
5. Igney, F. H., and Krammer P. H. Death and anti-death: tumour resistance to apoptosis. Nature Rev. Cancer, 2: 277-288, 2002.
6. Ashkenazi, A., and Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol., 11: 255-260, 1999.
7. Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K., and Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res., 59: 734-741, 1999.
8. Muller, I., Niethammer, D., and Bruchelt, G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int. J. Mol. Med., 1: 491-494, 1998.
9. Dudley, E., Hornung, F., Zheng, L., Scherer, D., Ballard, D., and Lenardo, M. NF-kappaB regulates Fas/APO-1/. Eur. J. Immunol., 29: 878-886, 1999.
10. Levkau, B., Scatena, M., Giachelli, C. M., Ross, R., and Raines, E. W. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-kappaB loop. Nat. Cell Biol., 1: 227-233, 1999.
11. Boland, M. P., Foster, S. J., and O'Neill, L. A. Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J. Biol. Chem., 272: 12952-12960, 1997.
12. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., and Galibert, L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (Lond.), 390: 175-179, 1997.
13. Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H. L., Steinman, R. M., and Choi, Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med., 186: 2075-2080, 1997.
14. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (Lond.), 397: 315-323, 1999.
15. Wang, R., Zhang, L., Zhang, X., Moreno, J., Luo, X., Tondravi, M., and Shi, Y. Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappaB ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation. J. Immunol., 166: 1983-1990, 2001.
16. Seitz, G., Stegmann, H. B., Jager, H. H., Schlude, H. M., Wolburg, H., Roginsky, V. A., Niethammer, D., and Bruchelt, G. Neuroblastoma cells expressing the noradrenaline transporter are destroyed more selectively by 6-fluorodopamine than by 6-hydroxydopamine. J. Neurochem., 75: 511-520, 2000.
17. Wagenknecht, B., Roth, W., Gulbins, E., Wolburg, H., and Weller, M. C2-ceramide signaling in glioma cells: synergistic enhancement of CD95-mediated, caspase-dependent apoptosis. Cell Death Differ., 8: 595-602, 2001.
18. Herr, I., and Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood, 98: 2603-2614, 2001.
19. Kaufmann, S. H., and Earnshaw, W. C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res., 256: 42-49, 2000.
20. Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E., and Bhalla, K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood, 96: 3900-3906, 2000.
21. Reed, J. C. Apoptosis-based therapies. Nature Rev. Drug Discov., 1: 111-121, 2002.
22. Josien, R., Wong, B. R., Li, H. L., Steinman, R. M., and Choi, Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol., 162: 2562-2568, 1999.
23. Galibert, L., Tometsko, M. E., Anderson, D. M., Cosman, D., and Dougall, W. C. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J. Biol. Chem., 273: 34120-34127, 1998.
24. Matsui, K., Fine, A., Zhu, B., Marshak-Rothstein, A., and Ju, S. T. Identification of two NF-kappaB sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. J. Immunol., 161: 3469-3473, 1998.
25. Harwood, F. G., Kasibhatla, S., Petak, I., Vernes, R., Green, D. R., and Houghton, J. A. Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J. Biol. Chem., 275: 10023-10029, 2000.
26. Wang, S., Kotamraju, S., Konorev, E., Kalivendi, S., Joseph, J., and Kalyanaraman, B. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem. J., 367: 729-740, 2002.